Levine, Douglas A.
Merck & Co., Inc.,
United States
2025 Rank: 44056
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Developmental Biology
Rank in SubField 1: 1301 out of 355674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 44056 | 47981 |
| Total Cites | 9295 | 9885 |
| H-index | 40 | 41 |
| Hm-index | 5 | 6 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 22 | 22 |
| Number of Single+First+Last Authored Papers | 40 | 40 |
| Total Cites to Single+First+Last Authored Papers | 570 | 587 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 7150 | 7445 |
| Ratio of Total Citations to Distinct Citing Papers | 1.30 | 1.33 |
| Self-Citation Percentage |
5.97%
|
|
Levine, Douglas A.
Merck & Co., Inc.,
United States
2024 Rank: 40443
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Developmental Biology
Rank in SubField 1: 1287 out of 334837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 40443 | 42542 |
| Total Cites | 9596 | 10347 |
| H-index | 42 | 44 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 15 | 15 |
| Number of Single+First+Last Authored Papers | 41 | 41 |
| Total Cites to Single+First+Last Authored Papers | 594 | 621 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 7233 | 7584 |
| Ratio of Total Citations to Distinct Citing Papers | 1.33 | 1.36 |
| Self-Citation Percentage |
7.26%
|
|
Levine, Douglas A.
Memorial Sloan-Kettering Cancer Center,
United States
2023 Rank: 30705
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Developmental Biology
Rank in SubField 1: 1083 out of 312644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 30705 | 32737 |
| Total Cites | 10507 | 11305 |
| H-index | 42 | 46 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 31 | 32 |
| Number of Single+First+Last Authored Papers | 41 | 41 |
| Total Cites to Single+First+Last Authored Papers | 621 | 652 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 7829 | 8203 |
| Ratio of Total Citations to Distinct Citing Papers | 1.34 | 1.38 |
| Self-Citation Percentage |
7.06%
|
|
Levine, Douglas A.
NYU Langone Health,
United States
2022 Rank: 32488
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Developmental Biology
Rank in SubField 1: 1217 out of 293195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 32488 | 34712 |
| Total Cites | 8945 | 9774 |
| H-index | 40 | 42 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 12 | 12 |
| Total Cites to Single+First Authored Papers | 32 | 32 |
| Number of Single+First+Last Authored Papers | 37 | 37 |
| Total Cites to Single+First+Last Authored Papers | 585 | 620 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 6603 | 6991 |
| Ratio of Total Citations to Distinct Citing Papers | 1.35 | 1.40 |
| Self-Citation Percentage |
8.48%
|
|
Levine, Douglas A.
NYU Langone Health,
United States
2021 Rank: 37969
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Developmental Biology
Rank in SubField 1: 1355 out of 271773 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 37969 | 40361 |
| Total Cites | 11999 | 13245 |
| H-index | 46 | 50 |
| Hm-index | 8 | 8 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 12 | 12 |
| Total Cites to Single+First Authored Papers | 48 | 48 |
| Number of Single+First+Last Authored Papers | 36 | 36 |
| Total Cites to Single+First+Last Authored Papers | 823 | 866 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 8778 | 9370 |
| Ratio of Total Citations to Distinct Citing Papers | 1.37 | 1.41 |
| Self-Citation Percentage |
9.41%
|
|
Levine, Douglas A.
NYU Langone Health,
2020 Rank: 28276
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Developmental Biology
Rank in SubField 1: 1004 out of 230678 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 28276 | 30377 |
| Total Cites | 7503 | 8346 |
| H-index | 41 | 42 |
| Hm-index | 7 | 7 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 1 | 1 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 39 | 39 |
| Number of Single+First+Last Authored Papers | 37 | 37 |
| Total Cites to Single+First+Last Authored Papers | 595 | 643 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 5509 | 5917 |
| Ratio of Total Citations to Distinct Citing Papers | 1.36 | 1.41 |
| Self-Citation Percentage |
10.10%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.